Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Silo Pharma, Inc. (SILO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6200-0.0300 (-1.82%)
At close: 03:27PM EDT
1.7000 +0.08 (+4.94%)
After hours: 06:14PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Downside Breakout

Downside Breakout

Performance Outlook
Previous Close1.6500
Open1.6000
Bid1.6000 x 1100
Ask1.7500 x 1300
Day's Range1.6068 - 1.7383
52 Week Range1.6068 - 6.5600
Volume5,119
Avg. Volume312,167
Market Cap5.036M
Beta (5Y Monthly)-0.70
PE Ratio (TTM)N/A
EPS (TTM)-1.6200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SILO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Silo Pharma, Inc.
    WPM: Lowering target price to $35.00WHEATON PRECIOUS METALS CORP has an Investment Rating of SELL; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

    Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New

  • GlobeNewswire

    Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

    Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD CLIFFS, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the initiation of an exploratory feasibility study evaluating a selected

  • GlobeNewswire

    Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

    Clarivate will monitor, manage, and maintain Company’s expanding IP portfolio ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of Clarivate™, a leading global provider of information services including IP lifecycle management solutions. Under terms of the agreement, Clariva

Advertisement
Advertisement